Vericel, MediWound Report That FDA Has Determined Application For MexoBrid Cannot Be Approved In Its Present Form
MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter